Антикоагулантна терапија и реверзија антикоагулантног ефекта

Reversal of antithrombotic agents. (отвара нови прозор)

Bauer KA.

Извор‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Индекс‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (отвара нови прозор)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (отвара нови прозор)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Извор‎: J Thromb Haemost 2015;13(10):1790-8.

Индекс‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (отвара нови прозор)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (отвара нови прозор)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Извор‎: N Engl J Med 2019;380(14):1326-35.

Индекс‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (отвара нови прозор)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (отвара нови прозор)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Извор‎: N Engl J Med 2016;375(12):1131-41.

Индекс‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (отвара нови прозор)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (отвара нови прозор)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Извор‎: Circulation 2011;124(14):1573-9.

Индекс‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (отвара нови прозор)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (отвара нови прозор)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Извор‎: Lancet 2015;385(9982):2077-87.

Индекс‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (отвара нови прозор)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (отвара нови прозор)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Извор‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Индекс‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (отвара нови прозор)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (отвара нови прозор)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Извор‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Индекс‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (отвара нови прозор)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (отвара нови прозор)

Levi M, Eerenberg E, Kamphuisen PW.

Извор‎: J Thromb Haemost 2011;9(9):1705-12.

Индекс‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (отвара нови прозор)

Emergency reversal of warfarin anticoagulation. (отвара нови прозор)

Lin Y, Callum J.

Извор‎: CMAJ 2010;182(18):2004.

Индекс‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (отвара нови прозор)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (отвара нови прозор)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Извор‎: Thromb Haemost 2012;108(2):217-24.

Индекс‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (отвара нови прозор)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (отвара нови прозор)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Извор‎: J Thromb Haemost 2008;6(4):622-31.

Индекс‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (отвара нови прозор)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (отвара нови прозор)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Извор‎: Blood Adv 2019;3(2):158-67.

Индекс‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (отвара нови прозор)

Idarucizumab for dabigatran reversal. (отвара нови прозор)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Извор‎: N Engl J Med 2015;373(6):511-20.

Индекс‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (отвара нови прозор)

Idarucizumab for dabigatran reversal - full cohort analysis. (отвара нови прозор)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Извор‎: N Engl J Med 2017;377(5):431-41.

Индекс‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (отвара нови прозор)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (отвара нови прозор)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Извор‎: Blood 2003;102(13):4594-9.

Индекс‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (отвара нови прозор)

Role of agents for reversing the effects of target-specific oral anticoagulants. (отвара нови прозор)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Извор‎: Am J Health Syst Pharm 2017;74(2):54-61.

Индекс‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (отвара нови прозор)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (отвара нови прозор)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Извор‎: Anesth Analg 2011;113(4):703-10.

Индекс‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (отвара нови прозор)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (отвара нови прозор)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Извор‎: J Am Coll Cardiol 2017;70(24):3042-67.

Индекс‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (отвара нови прозор)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (отвара нови прозор)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Извор‎: World Neurosurg 2014;81(1):110-5.

Индекс‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (отвара нови прозор)

Reversal of warfarin-induced hemorrhage in the emergency department. (отвара нови прозор)

Zareh M, Davis A, Henderson S.

Извор‎: West J Emerg Med 2011;12(4):386-92.

Индекс‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (отвара нови прозор)

ИНТЕНЗИВНА НЕГА

Антикоагулантна терапија и реверзија антикоагулантног ефекта

српски (ћирилица)

Антикоагулантна терапија и реверзија антикоагулантног ефекта

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Антикоагулантна терапија и реверзија антикоагулантног ефекта

Reversal of antithrombotic agents. (отвара нови прозор)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (отвара нови прозор)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (отвара нови прозор)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (отвара нови прозор)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (отвара нови прозор)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (отвара нови прозор)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (отвара нови прозор)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (отвара нови прозор)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (отвара нови прозор)

Emergency reversal of warfarin anticoagulation. (отвара нови прозор)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (отвара нови прозор)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (отвара нови прозор)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (отвара нови прозор)

Idarucizumab for dabigatran reversal. (отвара нови прозор)

Idarucizumab for dabigatran reversal - full cohort analysis. (отвара нови прозор)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (отвара нови прозор)

Role of agents for reversing the effects of target-specific oral anticoagulants. (отвара нови прозор)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (отвара нови прозор)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (отвара нови прозор)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (отвара нови прозор)

Reversal of warfarin-induced hemorrhage in the emergency department. (отвара нови прозор)

Контакт с локалним представницима

Медицинске информације

Филмови

Антикоагулантна терапија и реверзија антикоагулантног ефекта

Изабери језик

Подели